secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001125345-23-000063
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics to receive $15M milestone from Incyte after FDA approval of ZYNYZ
-----------------------------------------------------------------------------

- MacroGenics will receive $15M milestone payment from Incyte after FDA approval of ZYNYZ (retifanlimab-dlwr) for Merkel cell carcinoma.
- ZYNYZ, a PD-1 inhibitor, was originally developed by MacroGenics and licensed to Incyte in October 2017.
- This marks the third product approval from MacroGenics' pipeline of proprietary or partnered candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000063/0001125345-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000063/mgnx-20230322.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer